Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
作者： S. Vatrano , L. Righi , T. Vavalá , I. Rapa , M. Busso
DOI: 10.1007/S11523-015-0383-8
关键词:
摘要: Background Recently, in advanced non-small cell lung cancer (NSCLC), standard chemotherapy was flanked by biological agents directed against genomic abnormalities, including EGFR and ALK alterations, that significantly improved patient outcome. Despite these achievements, tumour progression almost always occurs a reassessment of the genetic profile may contribute to modulating therapeutic regimen. Resampling provide tissue for additional tests detect acquired resistance and/or new but currently available information is limited.
springer.com
sci-hub.se 参考文章(31)
Tony Mok, L. Zhang, Yi Long Wu, A small step towards personalized medicine for non-small cell lung cancer. Discovery Medicine. ,vol. 8, pp. 227- 231 ,(2009)
Ozgur Cem Erkin, Jhingook Kim, Jin Seok Ahn, Jungsuk An, Myung Ju Ahn, Jinwon Seo, Keunchil Park, Young Mog Shim, Young Kee Shin, Yoon La Choi, Kyung Song, Sanghui Park, Chang Ok Sung, Joungho Han, High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histology and Histopathology. ,vol. 27, pp. 197- 207 ,(2012) , 10.14670/HH-27.197
Baoping Guo, Hong Cen, Xiaohong Tan, Wenjian Liu, Qing Ke, Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0099399
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Marc Ladanyi, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Journal of Thoracic Oncology. ,vol. 8, pp. 823- 859 ,(2013) , 10.1097/JTO.0B013E318290868F
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
Maureen F Zakowski, Marc Ladanyi, Mark G Kris, None, EGFR mutations in small-cell lung cancers in patients who have never smoked The New England Journal of Medicine. ,vol. 355, pp. 213- 215 ,(2006) , 10.1056/NEJMC053610
Jane E. Visvader, Geoffrey J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nature Reviews Cancer. ,vol. 8, pp. 755- 768 ,(2008) , 10.1038/NRC2499
Gabriele Minuti, Armida D'Incecco, Lorenza Landi, Federico Cappuzzo, Protein kinase inhibitors to treat non-small-cell lung cancer Expert Opinion on Pharmacotherapy. ,vol. 15, pp. 1203- 1213 ,(2014) , 10.1517/14656566.2014.909412
Yi-Long Wu, Masahiro Fukuoka, Tony S.K. Mok, Nagahiro Saijo, Sumitra Thongprasert, James C.H. Yang, Da-Tong Chu, Jin-Ji Yang, Yuri Rukazenkov, Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. ,vol. 81, pp. 280- 287 ,(2013) , 10.1016/J.LUNGCAN.2013.03.004
Alice T. Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O'Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne, Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 2385- 2394 ,(2013) , 10.1056/NEJMOA1214886